Pregnancy-associated plasma protein-A (PAPP) promotes breast cancer progression

Jun Zhang*, Yuan Zhang†, Lanjiang Li‡, Yinghua Nian§, Ying Chen‖, Ruoxia Shen¶, and Xiaoyan Ma**

*Department of Clinical Laboratory, The Fifth Hospital of Wuhan, Wuhan, China; †Department of Ultrasound Medicine, Yunnan Cancer Hospital, the Third Affiliated Hospital of Kunming Medical University, Kunming, China; §Department of Forensic Medicine, Kunming Medical University, Kunming, China; ‡Department of Epidemiology and Biostatistics, School of Public Health, Kunming Medical University, Kunming, China; ‖Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China

ABSTRACT

Breast cancer is the most common malignancy in females and poses a significant health threat to women. Pregnancy-associated plasma protein-A (PAPP) is highly expressed in pregnancy-associated breast cancer (PABC) tissues. In this study, we investigated the functional role of PAPP in regulating the malignant phenotype of breast cancer. We first examined the expression level of PAPP in PABC tissue and breast cancer cell lines using quantitative real-time polymerase-chain reaction (qRT-PCR) and western blot. Next, the functional role of PAPP in breast cancer cells was validated by overexpression and knockdown experiments. Cell counting kit-8 (CCK-8) proliferation assay, 5-ethyl-2-deoxyuridine (EdU) incorporation assay, wound healing and transwell invasion assay were used to examine cell proliferation, migration, and invasion ability. We further identified the microRNA target regulating PAPP and studied its functional role. Finally, we examined the impact of PAPP on the tumorigenesis and metastasis of breast cancer in mice model. Our study revealed that PAPP was upregulated in PABC tissues and breast cancer cells. Overexpression of PAPP promoted cell proliferation, motility, invasion, and epithelial-mesenchymal transition (EMT). We further identified miR-497-5p as a negative regulator of PAPP, which suppressed cell proliferation, migration, invasion, and EMT in breast cancer cells. We also validated the oncogenic role of PAPP in the mouse xenograft model. Collectively, our study suggests that PAPP is an oncogenic protein highly expressed in PABC tissues and promotes breast cancer progression, which could serve as a novel therapeutic target for breast cancer.

1. Introduction

Breast cancer is the most frequent type of malignancy and the primary cause of cancer-related death in women [1]. Among all forms of cancers, female breast cancer prevalence and the illness burden have expanded considerably in recent years, which poses a serious public health threat globally [1–3]. With the delay of reproductive age...
in women, the odds of breast cancer diagnosis during pregnancy is increasing [4,5]. Breast cancer during pregnancy (or pregnancy-associated breast cancer, PABC) refers to breast cancer detected during pregnancy or within 12 months following delivery. Due to the natural expansion of the breast during pregnancy, the density and nodules in the breast also rises proportionately. It is therefore difficult for the physician to distinguish normally growing breast nodule form the abnormal tumor nodule of PABC [4,5]. In addition, since the chemotherapeutics for breast cancer treatment are detrimental to the fetus, it is difficult to apply standard treatment during pregnancy. In addition, there are only limited studies regarding the diagnosis, treatment, and prognosis of PABC, and clinical evidence is restricted to retrospective studies and case reports [6]. Although the frequency and mortality of breast cancer in Chinese population remains relatively low, there is a tendency of increasing breast cancer diagnosis in recent years [7,8].

According to previous research, PABC is an endocrine-dependent breast cancer [4,5]. However, based on the current literatures, different studies showed discrepancy on the prognosis of PABC [9,10]. Some studies suggest that there is no substantial difference in prognosis between PABC and non-PABC with the same clinical stage and treatment. In contrast, other studies indicate that the prognosis of PABC is poorer as a result of delayed diagnosis. A few studies highlighted that the alterations in the breast tissue microenvironment during nursing may have a significant implication in PABC prognosis in addition to the intrinsic feature of tumor [11,12]. Besides the fundamental principles of comprehensive breast cancer therapy, PABC treatment should minimize the risk to the developing fetus, and early diagnosis is critical for practical therapy to improve prognosis [13].

Pregnancy-associated plasma protein A (PAPPA) is a protein encoded by the human gene PAPPA [14]. PAPPA is a metalloproteinase secreted by human placenta, and it can interact with IGF-binding proteins (IGFBPs) to regulate the proteolysis and the bioavailability of insulin-like growth factor (IGF) [15,16]. The proteolytic activity of PAPPA is activated after binding to collagen, which is implicated in many biological processes, such as wound healing and bone remodeling [15,16]. A low level of PAPPA in plasma is considered as a biochemical marker for aneuploidy fetuses (fetuses with abnormal chromosome numbers) in pregnancy. For example, PAPPA can be used as a biomarker for Down’s syndrome screening in the prenatal diagnosis [17–19]. Low levels of PAPPA may also indicate the developmental dysfunction of placenta, which may be associated with undesirable complications, such as intrauterine growth restriction, pregnancy toxemia, early placental abruption, premature delivery, and stillbirth [20,21].

In this study, we aimed to investigate the potential role of PAPPA in regulating breast cancer progression. We first examined the expression level of PAPPA in PABC tissue and breast cancer cell lines. Gain- and loss-of-function experiments were performed in breast cancer cells to validate the functional role of PAPPA. We further identified the microRNA target regulating PAPPA and studied its functional role. Finally, we validated the implication of PAPPA in the tumorigenesis and metastasis of breast cancer in mice model.

2. Materials and methods

2.1 Patient sample collection

Pregnancy-associated breast cancer (PABC) tissues and the adjacent normal breast tissues were collected by surgery from a total number of 30 patients in Yunnan Cancer Hospital (The Third Affiliated Hospital of Kunming Medical University). We also collected the blood from 30 PABC patients and 30 healthy controls. The samples were snap-frozen in liquid nitrogen before further use. The study was approved by the Ethics Committee of the Third Affiliated Hospital of Kunming Medical University (KMU-20181011). All patients enrolled in this study signed the informed consent.

2.2 Reagents

BT549, MDA-MB-468, T47D, MDA-MB-231, MCF-7, and MCF-10A cell lines were purchased from Shanghai Kanglang Biological (Shanghai, China). DMEM/F12 medium was purchased from Thermo Fisher Scientific Inc (Manassas, VA, USA).
Fetal Bovine Serum was obtained from Gibco Life Technologies (Manassas, VA, USA). CCK-8 and IH staining were purchased from Beyotime Biotech. (Shanghai, China). EDU staining proliferation kit was purchased from Applied BioProbes (Rockville, MD, USA). Transwell chamber was provided by Corning (NY, USA). si-NC (control siRNA) and PAPPA-specific siRNA used for gene silencing were synthesized by Promega (Beijing, China). Plasmid for PAPPA overexpression (pcDNA-PAPPA) and microRNA mimics was synthesized by RiboBio (Guangzhou, China). Anti-PAPPA Antibody was purchased from Atlas Antibodies (HPA001667, Lund, Sweden). Recombinant PAPPA protein (2487-ZNF-020) was purchased from R&D Systems (Minneapolis, MN, USA).

2.3 Cell culture, transfection and passage

The temperature of the thermostatic water bath was adjusted to 37°C in advance and the frozen cells were retrieved from the liquid nitrogen to the water bath. The cryovial was shaken in the water for rapid thawing over 1 minute. Melted cells were transferred into 15 ml tube containing 10 ml fresh medium. After centrifugation at 2000 rpm for 2 min, the supernatant was discarded. The cell pellet was resuspended in DMEM/F12 medium containing 10% FBS at 37°C humidified incubator with 5% CO2. When the cell density reaches 80% ~90%, the medium was discarded. After PBS wash, cells were sub-cultured in a new cell culture dish with fresh medium.

For transfection, cells were seeded in a 6-well plate until 80% confluence. Cells were transfected with 100 nM siRNA or 6 µg plasmid DNA using Lipofectamine 2000 (Invitrogen, CA, USA) according to manufacturer’s instruction. After 16 h, the supernatant in the cell culture was discarded and fresh medium was replenished. Transfected cells were subjected to subsequent experiments 48 h post-transfection.

2.4 RNA extraction and real-time PCR

Trizol reagent (15,596,026, Thermo Fisher Scientific) was used to extract RNA from pregnancy-associated breast cancer tissues and breast cancer cells according to the manufacturer’s instructions. Purified total RNA was dissolved in DEPC water and its concentration was measured with NanoDorp. 1 µg of total RNA was used for cDNA synthesis by RevertAid First-Strand cDNA Synthesis Kit (K1622, Thermo Fisher Scientific). The resulted cDNA was analyzed in a 7500 Real-Time PCR System (Applied Biosystems/Life Technologies, Carlsbad, CA, USA) using SYBR premix EX TAQ II kit (RR820A, Takara, Dalian, China). The following PCR cycling condition was used: 95°C 5 min, 40 cycles of 95°C 30 sec, 60°C 15 sec and 72°C 30 sec, with signal detection at the end of each cycle. 2–ΔΔCt method was used to analyze the relative expression level with GAPDH as the internal reference gene. All primer sequences were synthesized by Shanghai Sangon Biotechnology Co., Ltd. (Shanghai, China):

- PAPPA (forward) 5'-ATGTGACCTTTGCTGGAAAG-3'; (reverse) 5'-CTGGACTCAGGGCTCAG-3'.
- GAPDH (forward) 5'-ACCCAGAAGACTGCGGATGGG-3'; (reverse) 5'-TTCAGCTCAGGGATGACCT-3'.

2.5 Protein extraction and western-blotting

Total protein was extracted from cells or tissues using RIPA lysis buffer containing protease inhibitor cocktail (Thermo Fisher Scientific 78,429, Waltham, MA, USA). Cells suspended in RIPA buffer were lysed on ice for 10 min and lysed cells were centrifuged at 14,000 rpm for 10 min. The supernatant containing total protein lysate was quantified by a BCA Protein assay kit (Beyotime Biotechnology, P0009; Shanghai, China). 10 µg protein sample was mixed with loading buffer and boiled for 10 min at 100°C. Protein samples were separated by SDS-PAGE electrophoresis in 10–12% SDS-PAGE gel. Separated protein was transferred from the gel to the PVDF membrane (BioRad 1,620,177, Irvine, CA, USA). After blocking with 5% skimmed milk for 1 h, the membrane was then incubated with primary antibodies overnight: anti-PAPPA (1:500), anti-E-cadherin (1:1000), anti-N-cadherin (1:1000), anti-vimentin (1:300) (all from Abcam, Cambridge, UK). Antibody against GAPDH (1:200, Wandlebio, Shenyang, China). The
membrane was washed 3 times with TBST buffer. After wash, the membrane was further incubated with HRP-linked secondary antibody (1:3000; Cell signaling #7074, MA, USA) at room temperature for 1 h. The membrane was washed four times with TBST and the protein bands were developed using BeyoECL Plus Kit (Beyotime Biotechnology, P0018S; Shanghai, China), and photographed on a gel imager system (Bio-Rad, Hercules, CA, United States). The densitometry analysis was performed with Image J software.

### 2.6 CCK8 cell proliferation assay

After transfection, cells were seeded in to a 96-well plate at a density of 1500 cell/well and cultured in a humidified cell culture incubator for 0, 24, 48, and 72 h, respectively. 10 μL CCK8 reaction solution (Solarbio, CA1210, Beijing, China) was added to the cell culture at indicated time point and incubated for 2 h in a humidified cell culture incubator. The light absorption value (OD value) in each condition was captured at 450 nm wavelength on a Synergy H1 microplate reader (Winooski, Vermont, USA).

### 2.7 EdU incorporation assay

Fluor™ EdU Andy Fluor™ 555 Imaging Kit (Applied BioProbes, #A004, MD, USA) was used for the EdU incorporation assay. Cells were inoculated in 96-well plates at the density of 6000 cells/well. The EdU working solution was prepared by diluting in cell medium at the ratio of 1:1000, and 50 μL EdU working solution was added into each well for 2-h incubation. The medium was discarded and cells were washed twice with PBS, followed by fixation with 100 μL of 3.7% formaldehyde in PBS for 15 min at room temperature. After the removal of fixative solution, cells were washed twice with 100 μL of PBS with 3% BSA. Then, 100 μL of 0.5% Triton X-100 in PBS was added to each well for 20 min incubation. After the removal of the solution, 1 x Click-iT* reaction cocktail was prepared based on the manufacturer’s instruction and added to cells for 30 min incubation. The staining cocktail was removed and cells was washed twice with 100 μL of PBS with 3% BSA. Cells were counter-stained by 500 nM DAPI in PBS and the images were captured under Leica AM6000 microscope.

### 2.8 Cell migration (wound healing) and transwell invasion assay

Cell migration ability was assessed by wound healing assay. 5 x 10⁵ cells were seeded in 6 well plates to reach 80% confluence. A scratch wound was created using a sterile 200 μL pipette tip in the central region of each well and the floating cells were removed. The cells were further incubated at 37°C for 24 h. Cell images were captured using an inverted light microscope (Leica AM6000 microscope). The migration distance was analyzed using ImageJ software. The relative migration distance was calculated as ratio of (would distance at 0 h – would distance at 24 h)/would distance at 0 h.

Cell invasion ability was examined by Transwell invasion assay. Cells were trypsinized and resuspended in serum-free medium. The transwell upper chamber (Corning, NY, USA, #3401) coated with Matrigel (BD Biosciences, Bedford, MA, USA, # 356,234) was used for invasion assay. 5 x 10⁵ cells were inoculated into the transwell upper chamber in serum-free medium and 2 mL of 10% serum-containing medium was added to the lower chamber. After 18 h, culture medium was discarded and cells were fixed with 4% paraformaldehyde at room temperature for 10 min. Fixed cells were stained with 0.5% crystal violet (Sigma, Germany, #109,218) for 20 min, and were photographed under Leica AM6000 microscope.

### 2.9 ELISA detection of PAPPA in serum

Human PAPP-A ELISA Kit (# EHPAPPA, Invitrogen) was used to quantified the serum PAPPA level. Briefly, the serum sample was diluted 2-fold in 1X Assay Diluent D buffer. Lyophilized PAPPA protein standard was diluted in 1X Assay Diluent D to prepare 5-fold dilution series. 100 μL standards or diluted samples were added to the 96-well plate coated with anti-PAPPA antibody for 2-h incubation. After
a wash step to remove unbound material, 100 µL biotin-labeled detection antibody was added for 1 h-incubation, which was followed by 45-min incubation with 100 µL streptavidin-HRP solution. After 4 washes with 1X wash buffer, chemiluminescent detection reagents (TMB solution) was added for signal development in the dark for 30 min, and the optical density of samples and standards was measured at 450 nm using a microplate reader (Infinite 200 PRO; Tecan). The concentration of PAPPA was measured based on the linear regression of the standards.

2.10 Xenograft tumorigenesis model

All animal procedures were reviewed and approved by the ethics committee of experimental animals at the Kunming Medical University. A total number of 10 female immunodeficient nude mice (weighing 30–40 g) were subcutaneously injected with MDA-MB-231 cells (1 × 10⁷ cells in 0.2 mL PBS) on the right flank. The mice were randomly divided into two groups (5 mice in each group): (1) Vector (injected with PBS every three days), (2) p-PAPPA (injected with recombinant p-PAPPA protein 5 mg per 100 g body weight every three days). Tumor volume was monitored every 5 days until day 35. The tumor volume was calculated using the formula: \( V(\text{tumor}) = 0.5 \times \text{length} \times \text{width}^2 \). Five weeks after tumor cell inoculation, all the mice were euthanized by CO2 asphyxiation. Mice were placed into the euthanizing chamber for 10 min until no movement was observed. Death was assured by subsequent cervical dislocation. The tumors of terminally dead mice were resected for weight measurement.

2.11 Immunohistochemistry (IHC) staining

For IHC staining, 4-mm sections of formalin-fixed paraffin-embedded (FFPE) tumor tissue were first deparaffinized in xylene and dehydrated in ethanol series. The antigen unmasking was performed by heating the section in citrate unmasking solution (SignalStain® Citrate Unmasking Solution (10X) (#14,746), Cell Signaling Technologies) for 10 min at a sub-boiling temperature (95°–98°C). After cooling, sections were washed in dH2O three times for 5 min each and then incubated in 3% hydrogen peroxide for 10 min. After three times washes in TBST buffer, the section was blocked for 1 h in 5% normal goat serum, and then incubated with primary antibodies overnight at 4°C: anti-PAPPA (1:500) and anti-Ki-67 (1:1000) (all from Abcam, Cambridge, UK). Then antibody solution was discarded and the section was washed three times using TBST buffer. The section was soaked with 1–3 drops SignalStain® Boost Detection Reagent (HRP, Rabbit #8114, Cell Signaling Technologies) for 30 min at room temperature. 200 µl SignalStain® substrate (#8059, Cell Signaling Technologies) was added for signal development. After 10 min, the section was washed in dH2O two times and then dehydrated. Section was mounted using the mounting medium (#14,177, Cell Signaling Technologies) and was imaged under Leica AM6000 microscope.

2.12 Hematoxylin and Eosin (HE) staining

HE staining was performed using H&E Stain Kit (ab245880, Abcam). Deparaffinized/hydrated lung tissue section was incubated in adequate Hematoxylin, Mayer’s (Lillie’s Modification) to completely cover tissue section and incubate for 5 min. The section was rinsed twice with distilled water to remove excess stain. Then, adequate Bluing Reagent was applied to completely cover tissue section and incubate for 30 secs. After washing with distilled water, the section was dehydrated in absolute alcohol, followed by staining with Eosin Y Solution to completely cover tissue for 2–3 min. The section was rinsed using absolute ethanol for three times and then mounted to a slide, and the images were collected under Leica AM6000 microscope.

2.13 Statistical analysis

All data were analyzed and graphed using SPSS19.0 and Prism9 software. The data were presented at mean ± standard deviation. The statistical difference between two groups was compared using unpaired student’s t tests. Comparisons among multiple groups were
analyzed using one-way analysis of variance (ANOVA) with Tukey’s post hoc test for pairwise comparison. Comparisons of data at multiple time points were examined using two-way ANOVA. Spearman correlation analysis was performed to determine the correlation between two genes. $P < 0.05$ was considered to be statistically different.

3. Results

Pregnancy-associated plasma protein-A (PAPPA) is a highly expressed protein in pregnancy-associated breast cancer (PABC) tissues. In this study, we investigated the potential role of PAPPA in modulating the malignant phenotype of breast cancer. Our study revealed that PAPPA was upregulated in PABC tissues and breast cancer cells. PAPPA overexpression promoted cell proliferation, motility, invasion, and epithelial–mesenchymal transition (EMT). We further identified miR-497-5p as a negative regulator of PAPPA, which suppressed cell proliferation, migration, invasion, and EMT in breast cancer cells. The oncogenic role of PAPPA was validated in the mouse xenograft model.

3.1 PAPPA is upregulated in PABC tissues and cells

We first detected the expression level of PAPPA in PABC tissue and the adjacent normal tissues by qRT-PCR. We observed the significant upregulation of PAPPA in PABC tissues (Figure 1(a)). Immunohistochemistry (IHC) staining revealed that in PABC tissues, the protein level of PAPPA was significantly elevated (Figure 1(b), n = 3 patients), which was further confirmed by western blot (Figure 1(c)). We further compared the expression levels of PAPPA in breast cancer cell lines (T47D, MCF-7, BT549, and MDA-MB-231 and MDA-MB-468) and normal breast epithelial MCF-10A cells. The results from qRT-PCR and western blot consistently showed the elevated expression level of PAPPA in breast cancer cell lines (Figures 1(d,e)).

3.2 Overexpression of PAPPA promotes proliferation, migration and invasion of breast cancer cells

To investigate the functional role of PAPPA in breast cancer cells, we transfected MDA-MB-231 and MCF7 with pcDNA-PAPPA plasmid to over-express PAPPA. The transfection of pcDNA-PAPPA caused significant upregulation of PAPPA at protein level (Figure 2(a)). CCK-8 proliferation assay revealed that PAPPA overexpression increased the cell proliferation (Figure 2(b)). Furthermore, EdU incorporation assay showed that PAPPA overexpression increased the number of cells actively replicating the DNA in the S phase (Figure 2(c)). We further performed wound-healing migration assay and transwell invasion assay. The results showed that PAPPA overexpression promoted cell migration and invasion ability (Figures 2(d, e)). In addition, we analyzed the cellular markers of EMT (E-cadherin, N-cadherin and vimentin) in MDA-MB-231 and MCF7 cells by western blot. Overexpression of PAPPA increased the levels of N-cadherin and vimentin but decreased protein levels of E-cadherin (figure 2f). Together, the above data suggest that PAPPA overexpression promotes the malignant phenotype of breast cancer cells.

3.3 Knocking down PAPPA inhibits the proliferation, migration and invasion of breast cancer cells

We next attempted to study the loss-of-function of PAPPA in breast cancer cells. Since the expression of PAPPA was relatively high in BT549 and MDA-MB-468 cells (Figures 1(d,e)), we transfected the two cell lines with siRNA targeting PAPPA (si-PAPPA), which could significantly downregulate the protein level of PAPPA (Figure 3(a)). CCK-8 proliferation assay revealed that PAPPA silencing suppressed the cell proliferation (Figure 3b). Consistently, EdU incorporation assay showed that PAPPA silencing reduced the number of EdU-positive cells in the S phase (Figure 3(c)). Wound-healing migration assay and transwell invasion assay further showed that PAPPA knockdown impaired cell migration and invasion ability.
Figure 1. PAPPA was highly expressed in pregnancy-associated breast cancer (PABC) tissues and cells.
(a) mRNA levels of PAPPA were significantly higher in pregnancy-associated breast cancer (PABC) tissues than in normal breast tissues (n = 30). (b) The expression of PAPPA in PABC tissues and normal breast tissues were measured by IHC staining (n = 3 patients, scale bar = 50 μm). (c) Western-blot was used to detect the protein level of PAPPA in PABC tissues and the adjacent normal tissues (n = 3 patients). (d) mRNA levels of PAPPA were examined by qRT-PCR in breast cancer cell lines (T47D, MCF-7, BT549, MDA-MB-231, and MDA-MB-468) and normal breast epithelial cell MCF-10A. (E) The protein level of PAPPA were detected by western blot in breast cancer cell lines (T47D, MCF-7, BT549, MDA-MB-231, and MDA-MB-468) and in normal breast epithelial cell MCF-10A. The data were analyzed using SPSS19.0 and Prism9 software. The data were presented at mean ± standard deviation. **P < 0.01, ***P < 0.001.
Figure 2. Overexpression of PAPPA promoted proliferation, migration and invasion of breast cancer cells. MDA-MB-231 and MCF7 cell lines with relatively low expression of PAPPA were selected for overexpression study. Cells were transfected with empty vector and pcDNA-PAPPA overexpression plasmid. (a) Western-blot was used to examine the overexpression of PAPPA after pcDNA-PAPPA transfection. (b) CCK-8 proliferation assay showed that overexpressing PAPPA significantly promoted cell proliferation. (c) EdU incorporation assay showed that overexpression of PAPPA increased the percentage of EdU positive cells. (d, e) Overexpression of PAPPA increased the migration and invasion ability in MDA-MB-231 and MCF7 cells. (f) Overexpression of PAPPA increased the levels of N-cadherin and vimentin (EMT markers) and decreased the protein levels of E-cadherin (epithelial marker). The data were analyzed using SPSS19.0 and Prism9 software. The data were presented at mean ± standard deviation. **P < 0.01, ***P < 0.001.
Figure 3. Knocking down PAPPA inhibited the proliferation, migration and invasion of breast cancer cells. BT549 and MDA-MB-468 with high PAPPA expressions were selected for knockdown experiments. Cells were transfected with si-NC (control siRNA) and si-PAPPA (siRNA targeting PAPPA). (a) Western-blot was used to examine PAPPA level after si-PAPPA silencing. (b) CCK-8 proliferation assay showed that silencing PAPPA significantly suppressed cell proliferation. (c) EdU incorporation assay showed that silencing of PAPPA decreased the percentage of EdU positive cells. (d, e) Silencing PAPPA impaired the migration and invasion ability in MDA-MB-231 and MCF7 cells. (f) PAPPA knockdown decreased the levels of N-cadherin and vimentin (EMT markers) and increased the protein level of E-cadherin (epithelial marker). The data were analyzed using SPSS19.0 and Prism9 software. The data were presented at mean ± standard deviation, **P < 0.01, ***P < 0.001.
Figure 4. Migratory capability of breast cancer cells is enhanced by co-culture with PAPPA-rich serum.

(a) The level of PAPPA in serum of PABC patients and healthy subjects were detected by ELISA. (b-e) MDA-MB-231 and MCF7 were cultured with healthy control serum (CS), PABC patient serum (PS) and PS in the presence of PAPPA-antagonizing antibody (PS+anti-PAPPA). (b) CCK-8 proliferation assay revealed that PABC serum treatment enhanced cell proliferation, which was partially inhibited by PAPPA antibody. (c) Wound-healing migration assay and (d) transwell invasion assay showed that PABC serum treatment promoted cell migration and invasion ability, which partially inhibited by PAPPA antibody. (e) PABC serum treatment upregulated EMT markers (N-cadherin and vimentin) and PAPPA antibody antagonized this effect. The data were analyzed using SPSS19.0 and Prism9 software. The data were presented at mean ± standard deviation. **P < 0.01, ***P < 0.001. (* indicates comparison between CS and PS; # indicates comparison between PS and PS+anti-PAPPA).
We also analyzed the cellular markers of EMT (E-cadherin, N-cadherin and vimentin) by western blot. The knockdown of PAPPA reduced the levels of N-cadherin and vimentin and increased E-cadherin protein level (figure 3(f)). The above data suggest that PAPPA is indispensable for the malignant phenotype of breast cancer cells.

### 3.4 Migratory capability of breast cancer cells is enhanced by co-culture with PAPPA-rich serum

To confirm the direct role of PAPPA protein on cellular function, we attempted to co-culture breast cancer cells with serum containing high level of PAPPA. We first performed ELISA to detect PAPPA level in serum from PABC patients and healthy control. We found that PAPPA protein level was significantly increased in PABC patients (Figure 4(a)). We then cultured MDA-MB-231 and MCF7 with healthy control serum (CS), PABC patient serum (PS), and PS in the presence of PAPPA-antagonizing antibody (PS+anti-PAPPA), CCK-8 proliferation assay revealed that PABC serum treatment enhanced cell proliferation, which was partially inhibited by PAPPA antibody (Figure 4(b)). Wound-healing migration assay and transwell invasion assay further showed that PABC serum treatment promoted cell migration and invasion ability, which partially inhibited by PAPPA antibody (Figures 4(c,d)). PABC serum treatment also upregulated EMT markers (N-cadherin and vimentin) and PAPPA antibody antagonized this effect (Figure 4(e)). Collectively, the above data suggest that elevated PAPPA protein level can directly regulate the malignant phenotype of breast cancer cells.

### 3.5 MiR-497-5p negatively targets PAPPA

We next sought to search for the potential microRNAs targeting PAPPA. Though the online miRNA databases: Starbase, TargetScan, miRD, and Tarbase database, we found that there were 14 miRNAs targeting PAPPA which were shared by the four databases. (Figure 5(a)). We next applied the microRNA mimics of 14 microRNAs in both MDA-MB-231 and MCF7 cell lines, and performed qRT-PCR to examine the effect of the overexpression of individual microRNA on PAPPA level. We found that only hsa-miR-497-5p mimic could significantly reduce PAPPA level (Figure 5(b)), which was also confirmed by western blot (Figure 5(c)). Interestingly, miR-497-5p expression level was significantly decreased in PABC tissues as compared to the adjacent normal tissues (Figure 5(d)). In addition, the expression of miR-497-5p was negatively correlated with PAPPA in PABC tissues (Figure 5(e)). The similar results were observed in the serum samples of PABC patients (Figures 5(F,G)). In addition, miR-497-5p level was significantly lower in breast cancer cell lines as compared to normal breast epithelial cell MCF-10A (Figure 5(h)). Collectively, the above data suggest that miR-497-5p is a negative regulator of PAPPA in breast cancer cells.

### 3.6 PAPPA overexpression rescues the inhibitory effect of miR-497-5p on cell proliferation, migration and invasion

We next studied the functional interaction between PAPPA overexpression and miR-497-5p. We found that transfection of MDA-MB-231 and MCF7 with miR-497-5p mimic inhibited cell proliferation, which was rescued by the co-transfection of pcDNA-PAPPA overexpression plasmid (Figure 6(a)). Wound-healing migration assay and transwell invasion assay further showed that miR-497-5p mimic also inhibited cell migration and invasion ability, which was rescued by PAPPA overexpression (Figures 6(b,c)). MiR-497-5p mimic also downregulated EMT markers (N-cadherin and vimentin) and upregulated E-Cadherin, and PAPPA overexpression antagonized this effect (Figure 6(d)). Therefore, PAPPA overexpression could abrogate the inhibitory effect of miR-497-5p on the cellular function of breast cancer cells.

### 3.7 PAPPA promotes the tumorigenesis and metastasis of breast cancer cells in vivo

To investigate the in vivo function of PAPPA, a total number of 10 female immunodeficient nude mice were subcutaneously injected with MDA-MB-231 cells. The mice were randomly
Figure 5. MiR-497-5p negatively targeted PAPPA.
(a) Venn Diagram showed that 14 miRNAs targeting PAPPA were predicted by Starbase, TargetScan, miRD and Tarbase database. (b) Cells were transfected with miRNA mimics, only miR-497-5p mimic reduced PAPPA mRNA levels. (c) Protein level of PAPPA was decreased by transfection with miR-497-5p mimic. (d) Expression of miR-497-5p was measured in PABC tissue and normal breast tissues by qRT-PCR. (e) Pearson correlation analysis between level of miR-497-5p and PAPPA in PABC cancer tissue. (f) Expression of miR-497-5p was measured in the serum of PABC patients and healthy subjects by qRT-PCR. (g) Pearson correlation analysis between level of miR-497-5p and PAPPA in PABC serum. (h) Expression of miR-497-5p was measured in breast cancer cell lines (T47D, MCF-7, BT549, MDA-MB-231 and MDA-MB-468) and in normal breast epithelial cell MCF-10A by qRT-PCR. The data were analyzed using SPSS19.0 and Prism9 software. The data were presented at mean ± standard deviation. **P < 0.01, ***P < 0.001.
Figure 6. Overexpression of PAPPA rescued the inhibitory effect of miR-497-5p on the proliferation, migration and invasion of breast cancer cells. 

(a) CCK-8 proliferation assay revealed that transfection of MDA-MB-231 and MCF7 with miR-497-5p mimic inhibited cell proliferation, which was rescued by the co-transfection of pcDNA-PAPPA overexpression plasmid. (b) Wound-healing migration assay and (c) transwell invasion assay further showed that miR-497-5p mimic also inhibited cell migration and invasion ability, which was rescued by PAPPA overexpression. (d) miR-497-5p mimic downregulated EMT markers (N-cadherin and vimentin) and upregulated E-Cadherin, and PAPPA overexpression antagonized the effect. The data were analyzed using SPSS 19.0 and Prism 9 software. The data were presented at mean ± standard deviation. **P < 0.01, ***P < 0.001. (*) indicates comparison between miR-NC and miR-497-5p; # indicates comparison between miR-497-5p and miR-497-5p+pcDNA-PAPPA.)
Figure 7. PAPPA promoted tumorigenesis and metastasis of breast cancer cells in vivo.
A total number of 10 female immunodeficient nude mice were subcutaneously injected with MDA-MB-231 cells. The mice were randomly divided into two groups (5 mice in each group): vector group (injected with PBS every three days) and p-PAPPA group (injected with recombinant p-PAPPA protein every three days). The injection of PAPPA significantly promoted the tumor growth (a) and tumor weight (b). (c) IHC staining of the cell proliferation marker Ki-67 and PAPPA in the tumor sections of the vector and p-PAPPA group (scale bar = 100 μm). (d) Hematoxylin and Eosin (HE) staining of lung tissue revealed increased number of metastatic nodules in the lung tissue in the group with PAPPA treatment (scale bar = 400 μm). The data were analyzed using SPSS19.0 and Prism9 software. The data were presented at mean ± standard deviation. **P < 0.01, ***P < 0.001.
divided into two groups (5 mice in each group): (1) Vector (injected with PBS every three days), (2) p-PAPPA (injected with recombinant p-PAPPA protein 5 mg per 100 g body weight every three days). Tumor volume were monitored every 5 days for 7 weeks. The injection of PAPPA significantly promoted the tumor growth and tumor weight (Figures 7(a,b)). We also stained the cell proliferation marker Ki-67 and PAPPA in the tumor sections. In the group injected with PAPPA recombinant protein, the cells stained with Ki-67 and PAPPA were significantly increased (Figure 7(c)). In addition, we also analyzed the metastasis in the lung tissue via Hematoxylin and Eosin (HE) staining. In the group with PAPPA treatment, the number of metastatic lung nodules was significantly increased in comparison to the vector group (Figure 7(d)). Together, these data suggest that PAPPA functions as a tumor-promoting factor for breast cancer in vivo.

4. Discussion

Breast cancer originates from the abnormal proliferation of mammary epithelial cells under the action of a variety of carcinogenic factors. At an early stage, clinical symptoms manifest in the forms of breast swelling and pain, nipple skin abnormality, lymph node enlargement [22]. Advanced breast cancer cells may metastasize to bone, lung, and liver along with blood circulation, which seriously threatens the life and health of patients [23,24]. The incidence of breast cancer ranks the first among female malignancies [22]. In China, the incidence of breast cancer is increasing year by year, and about 300,000 women are diagnosed with breast cancer each year [1–3]. With the improvement of the treatment strategies, the death rate of breast cancer has gradually decreased [25–27]. Although a variety of oncogenes have been implicated in breast cancer progression, the etiology of pregnancy-associated breast cancer (PABC) remains unclear. Previous studies have revealed that PAPPA expression is elevated in breast cancer cells, which promotes the proliferation, migration, and invasion of breast cancer cells [28,29]. Consistently, in our study, we revealed the upregulation of PAPPA in the PABC tumor tissues and serum. Through the loss-of-function and gain-of-function experiments, we demonstrated that PAPPA is indispensable for promoting the proliferation and metastasis of breast cancer cells in vitro and in vivo. In order to further identify the potential miRNA regulating PAPPA expression, we employed four online databases [30–33] to search for potential microRNAs of PAPPA. We validated that miR-497-5p is a negative regulator of PAPPA, which is downregulated in PABC tissue and serum.

PAPPA is initially identified in the serum of pregnant women and secreted by placental syncytiotrophoblast and decidua cells during pregnancy [34]. PAPPA is a member of the metal-binding protease family and plays an important role in regulating the insulin growth factor axis [15,16]. PAPPA can promote cell proliferation, inhibit apoptosis and promote the secretion of inflammatory cytokines [15,16]. Previous studies implicated PAPPA in the progression of precancerous breast nodule and invasive breast cancer [35,36]. Consistently, we showed that the injection of recombinant PAPPA protein could promote tumorigenesis and metastasis in the xenograft breast cancer mouse model. PAPPA could also regulate early mitosis and proliferation of breast cancer cells [37,38]. We also showed that silencing of PAPPA suppresses cell proliferation in breast cancer cells.

In order to further identify the potential miRNA regulating PAPPA expression, we employed four online databases (Starbase, TargetScan, miRD, and Tarbase database) [30–33] to search for potential microRNAs of PAPPA. We validated that miR-497-5p is a negative regulator of PAPPA, which is downregulated in PABC tissue and serum. miR-497-5p overexpression could decrease the invasion and migration ability of breast cells. In addition, PAPPA overexpression rescues the inhibitory impact of miR-497-5p on the cell invasion and migration in breast cancer. Based on these results, our data suggest that miR-497-5p is a tumor-suppressor targeting PAPPA in breast cancer cell. Further experiment is required to validate the tumor-suppressor function of miR-497-5p in mouse model.
5. Conclusions

PAPPA was highly expressed in PABC tissues and breast cancer cells. Overexpression of PAPPA promoted cell proliferation and metastasis of breast cancer cells in vitro and in vivo. miR-497-5p, which was downregulated in PABC tissues, was identified as a negative regulator of PAPPA. These data indicate that PAPPA upregulation contributes to the progression of PABC due to the downregulation of miR-497-5p. Future efforts are required to investigate the mechanism of miR-497-5p downregulation in PABC.

Highlights

• Pregnancy-associated plasma protein-A (PAPPA) is upregulated in breast cancer
• PAPPA overexpression promotes the malignant phenotype of breast cancer cells
• miR-497-5p is a negative regulator of PAPPA in breast cancer cells
• PAPPA promotes tumorigenesis and metastasis of breast cancer cells in mouse model

Disclosure statement

The authors declare no competing interests.

Author contribution

(I) Put forward the hypothesis and design this study: Xiaoyan Ma, Jun Zhang and Yuan Zhang; (II) Collect, analysis and check the data: Lanjiang Li, Yinghua Nian, Ying Chen and Ruoxia Shen; (III) Participate in writing and revising the manuscript: Jun Zhang and Yuan Zhang; (IV) Read and approved the final manuscript: All authors.

Funding

The author(s) reported there is no funding associated with the work featured in this article.

References

[1] Veronesi U, Boyle P, Goldhirsh A, et al. Breast cancer. Lancet. 2005;365(9472):1727–1741.
[2] DeSantis C, Siegel R, Bandi P, et al. Breast cancer statistics, 2011. CA Cancer J Clin. 2011;61(6):409–418.
[3] Liang Y, Zhang H, Song X, et al. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14–27.
[4] Peairs KS, Choi Y, Stewart RW, et al. Screening for breast cancer. Semin Oncol. 2017;44(1):60–72.
[5] Braden AM, Stankowski RV, Engel JM, et al. Breast cancer biomarkers: risk assessment, diagnosis, prognosis, prediction of treatment efficacy and toxicity, and recurrence. Curr Pharm Des. 2014;20(30):4879–4898.
[6] de la Mare JA, Contu L, Hunter MC, et al. Breast cancer: current developments in molecular approaches to diagnosis and treatment. Recent Pat Anticancer Drug Discov. 2014;9(2):153–175.
[7] Miller L, Smith EC. Breast cancer prognostic tests: helping patients understand testing results and their implications. Clin J Oncol Nurs. 2019;23(5):478–481.
[8] Khalil AI, Bendahhou K, Mestaghamni H, et al. Cancer du sein au Maroc: profil phénomotypique des tumeurs [Breast cancer in Morocco: phenotypic profile of tumors]. Pan Afr Med J. 2016;25:74.
[9] Vivanco M. Markers in breast cancer. Methods Mol Biol. 2010;593:137–156.
[10] An SM, Evans AJ, Lam TP, et al. How relevant is breast cancer screening in the Asia/Pacific region? Breast. 2007;16(2):113–119.
[11] Pinto R, De Summa S, Pilato B, et al. DNA methylation and miRNAs regulation in hereditary breast cancer: epigenetic changes, players in transcriptional and post-transcriptional regulation in hereditary breast cancer. Curr Mol Med. 2014;14(1):45–57.
[12] Li J, Shen L, Xiao XG, et al. MicroRNAs in breast cancer and breast cancer stem cells and their potential for breast cancer therapy. Chin Med J (Engl). 2013;126(13):2556–2563.
[13] Keshtgar M, Davidson T, Pigott K, et al. Current status and advances in management of early breast cancer. Int J Surg. 2010;8(3):199–202.
[14] Jin C, Gao S, Li D, et al. MiR-182-5p inhibits the proliferation of vascular smooth muscle cells induced by ox-ldl through targeting PAPPA. Int Heart J. 2020;61(4):822–830.
[15] Zhou Y, Ma W, Bia H, et al. Long non-coding RNA MIAT/miR-148b/PAPPA axis modifies cell proliferation and migration in ox-LDL-induced human aorta vascular smooth muscle cells. Life Sci. 2020;256:117852.
[16] Conover CA, Oxvig C. PAPP-A and cancer. J Mol Endocrinol. 2018;61(1):T1–T10.
[17] Yliniemi A, Makikallio K, Korpimaki T, et al. Combination of PAPPA, fhCGβ, AFp, PlGF, sTNFR1, and maternal characteristics in prediction of early-onset preeclampsia. 2015;Clin Med Insights Reprod Health. 9:13–20.
[18] Lu G, Chu Y, Tian P. Knockdown of H19 attenuates Ox-LDL-induced vascular smooth muscle cell proliferation, migration, and invasion by regulating miR-599/PAPPA axis. J Cardiovasc Pharmacol. 2021;77(3):386–396.
[19] Guo Y, Bao Y, Guo D, et al. Pregnancy-associated plasma protein a in cancer: expression, oncogenic functions and regulation. Am J Cancer Res. 2018;8(6):955–963.

[20] Heitzeneder S, Sotillo E, Shern JF, et al. Pregnancy-associated plasma protein-A (PAPP-A) in ewing sarcoma: role in tumor growth and immune evasion. J Natl Cancer Inst. 2019;111(9):970–982.

[21] Loddo M, Andrzsikiewicz J, Rodriguez-Acebes S, et al. Pregnancy-associated plasma protein A regulates mitosis and is epigenetically silenced in breast cancer. J Pathol. 2014;233(4):344–356.

[22] Cadoo KA, Traina TA, King TA. Advances in molecular and clinical subtyping of breast cancer and their implications for therapy. Surg Oncol Clin N Am. 2013;22(4):823–840.

[23] Dodiy-Manuel A, Wakama IE. Predispositions of carcinoma of the breast: a review. Niger J Med. 2014;23(1):7–12.

[24] He YS, Peng YL, Yang H, et al. Sichuan Da Xue Xue Bao Yi Xue Ban. 2020;51(1):30–34.

[25] Lerebours F. Traitements néoadjuvants du cancer du sein: marqueurs géno- et phénotyipques de la réponse thérapeutique et du pronostic [primary systemic therapy in breast cancer: clinical and molecular factors predictors of outcome and response]. Pathol Biol (Paris). 2006;54(4):209–214

[26] Arciero C, Somiari SB, Shriver CD, et al. Functional relationship and gene ontology classification of breast cancer biomarkers. Int J Biol Markers. 2003;18(4):241–272.

[27] Molina R, Barak V, van Dalen A, et al. Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol. 2005;26(6):281–293.

[28] Lerebours F, Lidereau R. Molecular alterations in sporadic breast cancer. Crit Rev Oncol Hematol. 2002;44(2):121–141.

[29] Huber KE, Carey LA, Wazer DE. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. Semin Radiat Oncol. 2009;19(4):204–210.

[30] Shen Y, Peng X, Shen C. Identification and validation of immune-related lncRNA prognostic signature for breast cancer. Genomics. 2020;112(3):2640–2646.

[31] Gonçalves A, Viens P, Sobol H, et al. Altérations moléculaires des cancers du sein: applications cliniques et nouveaux outils d’analyse [Molecular alterations in breast cancer: clinical implications and new analytical tools]. Rev Med Interne. 2005;26(6):470–478.

[32] Consuegra-Sanchez L, Fredericks S, Kaski JC. Pregnancy-associated plasma protein-A (PAPP-A) and cardiovascular risk. Atherosclerosis. 2009;203(2):346–352.

[33] Huang J, Tabata S, Kakiuchi S, et al. Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target. Oncotarget. 2013;4(8):1172–1184.

[34] Boldt HB, Conover CA. Pregnancy-associated plasma protein-A (PAPP-A): a local regulator of IGF bioavailability through cleavage of IGFBPs. Growth Horm IGF Res. 2007;17(1):10–18.

[35] Mansfield AS, Visscher DW, Hart SN, et al. Pregnancy-associated plasma protein-A expression in human breast cancer. Growth Horm IGF Res. 2014;24(6):264–267.

[36] Bulut I, Coskun A, Ciftci A, et al. Relationship between pregnancy-associated plasma protein-A and lung cancer. Am J Med Sci. 2009;337(4):241–244.

[37] Nakasato M, Kohsaka H, Mizutani T, et al. Pregnancy-associated plasma protein (PAPP)-A expressed in the mammary gland controls epithelial cell proliferation and differentiation. Endocrine. 2013;43(2):387–393.

[38] Boldt HB, Glærup S, Overgaard MT, et al. Definition, expression, and characterization of a protein domain in the N-terminus of pregnancy-associated plasma protein-A distantly related to the family of laminin G-like modules. Protein Expr Purif. 2006;48(2):261–273.